The Clinic Clause Samples

The Clinic. CompBioMed will target the clinical stakeholders, including health care professionals such as doctors and surgeons. We expect that computational modelling of the human body and physiology will impact the field of biomedicine by fundamentally altering the basis for the diagnosis and treatment of disease into a personalised, predictive, participatory and preventative process. In the future, medical innovation will be directed towards optimising treatments using integrated functional simulation in silico, assembling a customised computer model of a patient's condition across multiple organ systems and length scales (from molecular to human to population), across timescales from nanoseconds to years, and allowing for the influence of the environment. The quality and usability of our software will put us in an influential position in terms of promoting modelling and associated software standards internationally. The presence of clinical partners within our consortium will ensure that we exploit any potential impact of these modelling tools in a clinical context. Through integration into clinical decision support systems, computer based modelling and simulation will be able to advise courses of action ahead of treatments, including interventions, which will lead to improved outcomes for patients and enhance the health and wellbeing of the European Union. An important impact of the in silico technologies we are promoting will be to reduce, refine and eventually replace animal experimentation in biomedical research, putting simulation on an equal footing with sequencing and imaging. Various computational biomedicine projects that have developed advanced technologies are struggling to move to clinical trials phases because the technological expertise is lacking from many research hospitals. However, once any one of these computational workflows is established and put in use in a clinical setting, it is possible to amass hundreds of patient-specific simulations. Even if the primary data had to be destroyed on grounds of privacy, these data can be used to identify input parameter distributions that characterise well in silico populations, with respect to the particular pathophysiological process captured by the simulation. If these data can be combined with a simulation of an intervention, what we obtain are so-called ‘in silico clinical trials’, wherein a new surgical procedure, the insertion of a new medical device, or the assumption of a new drug is simulated with...